TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated, and produced at scale to meet urgent public health needs during emerging or re-emerging disease outbreaks. This contract focuses on building and validating Nucleic Acid Amplification Tests (NAATs) for high-priority pathogens that could spark future outbreaks or pandemics.
“ATCC is the global leader in providing authenticated, high-quality biological resources and standards that are essential for the acceleration of diagnostics, vaccines, and therapeutics,” said ATCC Federal Solutions Senior Vice President Rebecca Bradford, MBA, MS, PMP. “This award, which is one of many from the CDC, underscores how ATCC continues to support the CDC’s pandemic preparedness and emergency response to infectious disease threats. Rapidly developing diagnostic tests is essential for identifying cases early and guiding an effective national response.”
As part of the contract, ATCC, working with QIAGEN, will partner closely with the CDC to create and carry out a plan for the rapid development and validation of NAATs. The goal: be ready with scalable test production capacity before an outbreak hits.
ATCC is suited to meet these tasks as it already supports the CDC’s global surveillance of emerging pathogens and emergency response efforts through the International Reagent Resource (IRR), a centralized distribution hub for surveillance and diagnostic test kits. The IRR procures pathogen test components and assembles, qualifies, and distributes these kits to public health laboratories.
“Early testing is one of the most effective tools for preventing an outbreak from escalating,” Bradford added. “This award builds on ATCC’s long history supporting federal emergency response and enables us to deliver high-quality diagnostic materials to the CDC quickly and reliably.”
This work reflects ATCC’s ongoing commitment to strengthen global health security through trusted science and proven expertise.
Read more here.